insmed.com - Utang kumulatif perusahaan INSM

Insmed Incorporated is scaling its potential through alliances with clinics and biotech centers. Revenues are based on the sale of a unique drug for severe pulmonary infections. Stable management is successfully preparing the foundation for expansion. On GURU.Markets, this linear chart of total liabilities shows that the metric stands at 0.77.

This metric measures the total volume of borrowed capital, reflecting the business's dependence on external financing and the cost of servicing its obligations. The trend of this metric allows for an assessment of the issuer's credit risk and solvency. By analyzing the current debt status on GURU.Markets, an investor can see the growth rate of the debt. For Insmed Incorporated (INSM), this is critical due to the high liquidity burn associated with the development of new molecules. Increasing loans coupled with a limited drug portfolio heighten the company's financial vulnerability.